List of Excipients in Branded Drug EPINASTINE

Generic Drugs Containing EPINASTINE

Company	Ingredient	NDC	Excipient
Akorn	epinastine hydrochloride	17478-911	BENZALKONIUM CHLORIDE
Akorn	epinastine hydrochloride	17478-911	EDETATE DISODIUM
Akorn	epinastine hydrochloride	17478-911	HYDROCHLORIC ACID
Akorn	epinastine hydrochloride	17478-911	SODIUM CHLORIDE
Akorn	epinastine hydrochloride	17478-911	SODIUM HYDROXIDE
Akorn	epinastine hydrochloride	17478-911	SODIUM PHOSPHATE, MONOBASIC

What are the Most Frequently-Used Excipients in EPINASTINE?

# Of NDCs	Excipient
1	BENZALKONIUM CHLORIDE
1	EDETATE DISODIUM
1	HYDROCHLORIC ACID
1	SODIUM CHLORIDE
1	SODIUM HYDROXIDE
1	SODIUM PHOSPHATE, MONOBASIC

Epinastine Excipient Strategy and Commercial Opportunities

Last updated: August 29, 2026

Epinastine is an established antihistamine with limited active-ingredient exclusivity but continuing formulation opportunities in ophthalmic, nasal, and oral products. The strongest commercial prospects are preservative-free eye drops, multidose delivery systems, differentiated packaging, pediatric or geriatric dosage forms, and region-specific reformulations. The core molecule is genericized, so value depends on patient tolerability, stability, device performance, manufacturing efficiency, and regulatory positioning.

What is epinastine and which dosage forms are commercially relevant?

Epinastine hydrochloride is a selective histamine H1-receptor antagonist used primarily for allergic conjunctivitis. In the United States, epinastine ophthalmic solution is marketed at a 0.05% strength. The reference product, Elestat, was developed by Allergan and approved by the FDA in 1999. Generic epinastine ophthalmic solutions are available through the abbreviated new drug application pathway.[1]

Commercially relevant dosage forms include:

Dosage form	Typical use	Commercial status	Excipient opportunity
Ophthalmic solution, 0.05%	Allergic conjunctivitis	Genericized; multiple suppliers	Preservative-free, multidose, comfort, packaging
Oral tablets	Allergic rhinitis, asthma-related indications in some markets	Regionally marketed, particularly in Asia	Taste masking, orally disintegrating tablets, pediatric dosing
Nasal formulations	Allergic rhinitis	Market availability varies by jurisdiction	Mucoadhesion, spray performance, preservative reduction
Combination ophthalmic products	Allergy and ocular inflammation	Limited commercial penetration	Compatibility, viscosity, device differentiation

Epinastine is a small molecule. Biosimilar risk therefore does not apply. Competition comes from generic chemical equivalents and branded alternatives such as olopatadine, ketotifen, azelastine, bepotastine, and cromolyn.

What excipients are used in epinastine ophthalmic products?

The reference epinastine ophthalmic formulation uses a conventional aqueous system. The U.S. labeling identifies benzalkonium chloride as the preservative and includes phosphate buffers, sodium chloride, edetate disodium, hydrochloric acid or sodium hydroxide for pH adjustment, and purified water.[1]

A representative excipient architecture is:

Formulation function	Representative excipient	Strategic purpose
Antimicrobial preservation	Benzalkonium chloride	Protects a multidose aqueous product
Buffering	Sodium phosphate salts	Controls pH and supports chemical stability
Tonicity	Sodium chloride	Improves ocular tolerability
Chelation	Edetate disodium	Binds trace metals and can improve preservative performance
pH adjustment	Hydrochloric acid, sodium hydroxide	Establishes target pH
Vehicle	Purified water	Solubilizes epinastine hydrochloride

Generic products may use the same or comparable excipients while varying concentrations, container systems, or manufacturing controls. FDA-approved generic ophthalmic products must demonstrate pharmaceutical equivalence and bioequivalence through the applicable regulatory framework, but they can still differentiate through packaging, preservative systems, ease of use, and supply reliability.[2]

Why is benzalkonium chloride commercially important?

Benzalkonium chloride is effective and familiar to manufacturers, but chronic exposure can cause ocular-surface irritation, tear-film disruption, and epithelial toxicity in susceptible patients. The concern is most relevant to patients with dry eye disease, frequent dosing, contact-lens use, glaucoma therapy, or long-term treatment.[3]

This creates the clearest excipient opportunity in epinastine ophthalmics: replacing benzalkonium chloride with a preservative-free presentation or a lower-irritancy preservation system.

Potential alternatives include:

• Preservative-free unit-dose vials.
• Multidose containers with microbial-inhibiting valves.
• Container systems using silver-based or mechanical protection.
• Alternative preservatives such as polyquaternium-1, stabilized oxychloro complexes, or oxidative preservative systems.
• Reduced-preservative formulations supported by validated container-closure integrity.

Each alternative creates a different regulatory and manufacturing burden. A unit-dose product eliminates the need for a conventional preservative but increases packaging cost, filling complexity, shipping volume, and waste. A multidose preservative-free container reduces waste but requires device qualification, extractables and leachables testing, microbial ingress testing, and dose-delivery validation.

What excipient strategies offer the strongest product differentiation?

Preservative-free ophthalmic solution

A preservative-free epinastine eye drop is the most direct reformulation opportunity. The commercial rationale is strongest for:

• Patients with ocular-surface disease.
• Frequent users.
• Children requiring repeated seasonal treatment.
• Contact-lens wearers.
• Patients using multiple preserved ophthalmic products.

A single-dose vial is technically straightforward if epinastine hydrochloride remains chemically and physically stable in the selected vehicle. The main weaknesses are unit cost and patient inconvenience. A preservative-free multidose device can command a stronger commercial position but requires greater investment in device development and regulatory documentation.

Low-irritancy multidose formulation

A lower-irritancy multidose product may provide a middle path between standard preserved drops and unit-dose packaging. The formulation would need to balance:

• Microbial protection.
• Ocular comfort.
• Chemical stability.
• Compatibility with the dispensing system.
• Consistent delivered volume.

The excipient claim alone is unlikely to create durable protection. The stronger intellectual-property position would combine the excipient system with a defined concentration range, pH window, container technology, and microbial-performance specification.

Improved comfort and residence time

Increasing viscosity can reduce drainage and extend ocular residence time, but excessive viscosity can blur vision and impair drop administration. Candidate excipients may include hydroxypropyl methylcellulose, hydroxypropylcellulose, povidone, polyethylene glycol, hyaluronic acid, or other ophthalmic-grade polymers.

A viscosity-enhanced epinastine product could target patients who need longer ocular contact or who have difficulty administering multiple daily doses. The formulation must avoid changing the product’s clinical performance in a way that triggers a more demanding development program.

Enhanced solubility and stability

Epinastine hydrochloride is water-soluble, reducing the need for aggressive solubilizers. The main technical risks are likely to involve pH-dependent stability, oxidative degradation, light exposure, adsorption to packaging, and preservative compatibility.

Useful development tools include:

• Phosphate or non-phosphate buffer screening.
• Chelator optimization.
• Oxygen-control packaging.
• Light-protective containers.
• Low-peroxide excipients.
• Headspace management.
• Compatibility testing with elastomers and dispensing components.

A non-phosphate buffer may have commercial appeal where phosphate interaction with the ocular surface or manufacturing considerations are concerns. Any change must be supported by stability, tolerability, and container-closure data.

What formulation patents could protect epinastine products?

The molecule itself is old, and broad composition claims covering epinastine hydrochloride ophthalmic solution would face substantial validity and obviousness risk. A stronger patent strategy would focus on a technically specific product architecture.

Potential claim categories include:

Patent category	Potential claim subject	Relative strength
Preservative-free composition	Epinastine concentration, pH, tonicity, buffer and stabilizer ranges	Moderate if supported by unexpected stability or tolerability data
Multidose device	Valve, closure, microbial barrier and dose-delivery configuration	Moderate to strong if device-specific
Low-irritancy system	Alternative preservative and defined ocular-surface performance	Moderate
Stability	Specific degradation limits under accelerated conditions	Weak to moderate unless linked to a non-obvious formulation
Viscosity-enhanced product	Polymer concentration and residence-time profile	Moderate
Combination product	Epinastine with another active ingredient	Dependent on clinical and formulation evidence
Manufacturing process	Mixing, filtration, filling, sterilization, or oxygen-control process	Moderate where process improves quality or yield

The most defensible portfolio would combine composition, container, and method-of-use claims. A formulation patent that covers only routine excipient substitution is vulnerable to obviousness challenges. A patent that links a preservative-free formulation to a specific multidose device and validated microbial protection has a stronger commercial profile.

What patent expiration issues affect epinastine?

The original U.S. active-ingredient and product patents are long expired or no longer commercially significant. The practical U.S. barrier is therefore regulatory execution, not basic molecule exclusivity.

For current products, the key patent questions are:

1. Whether any formulation or device patent is listed in the FDA Orange Book.
2. Whether an ANDA applicant must make a Paragraph IV certification.
3. Whether the reference sponsor has initiated litigation under the Hatch-Waxman framework.
4. Whether any settlement restricts generic launch timing.
5. Whether later patents cover only a narrow reformulation rather than the widely marketed product.

The FDA Orange Book is the controlling source for listed patents and exclusivity information, while FDA labeling and approval records identify the approved formulation and reference product status.[2,4] No biosimilar framework applies because epinastine is a synthetic small molecule.

What is the Orange Book and Paragraph IV status of epinastine?

Epinastine ophthalmic products are subject to the ANDA framework rather than the abbreviated pathway used for biologics. A generic applicant can submit a Paragraph IV certification against an unexpired listed patent or use a Paragraph III certification where the patent is valid but not yet expired.

For an established genericized product, the commercial impact of Paragraph IV litigation is usually limited unless a later formulation or device patent is listed. The main launch scenarios are:

Scenario	Likely commercial effect
No unexpired listed patents	Generic launch can proceed after regulatory approval and applicable exclusivity
Narrow formulation patent	Generic may launch with a non-infringing formulation
Device patent	Launch may require a different container or dispensing system
Paragraph IV challenge	Litigation may delay launch or create settlement-driven entry timing
Authorized generic	Price pressure increases and branded reformulation value declines

A new preservative-free epinastine product may not receive meaningful market protection merely because its excipients differ from an older product. To obtain meaningful exclusivity, the sponsor would typically need a new drug application, a qualifying clinical or regulatory strategy, and patent claims directed to the reformulated product or its delivery system.

When does epinastine lose exclusivity?

Epinastine has already lost practical exclusivity for its core ophthalmic product in the United States. The reference product’s commercial protection is no longer based on an active-ingredient patent estate. Market entry is governed by generic approval, manufacturing capacity, supply contracts, and product differentiation.

Important exclusivity categories are:

Exclusivity type	Relevance to epinastine
New chemical entity exclusivity	Historical only; no current commercial effect
Orphan-drug exclusivity	Not a central feature of epinastine ophthalmic products
Pediatric exclusivity	Requires a specific qualifying FDA action; not assumed
180-day generic exclusivity	Depends on the first qualifying ANDA applicant
Formulation patent term	Relevant only if a later patent remains enforceable
Device or combination-product protection	Potentially relevant to reformulated products

A sponsor seeking renewed market protection would need to develop a differentiated product rather than rely on the legacy molecule.

How does epinastine compare with competing antihistamine eye drops?

Epinastine competes in a crowded allergy-ophthalmology market.

Product	Active ingredient	Common strength	Differentiation	Excipient opportunity
Epinastine ophthalmic	Epinastine HCl	0.05%	H1 antagonism and mast-cell stabilization activity	Preservative-free and comfort-focused products
Pataday and generics	Olopatadine HCl	0.1%, 0.2%, 0.7%	Strong brand recognition and once-daily positioning	Preservative-free and long-residence products
Zaditor and generics	Ketotifen fumarate	0.025%	OTC access and broad consumer familiarity	Unit-dose and low-irritancy systems
Bepreve and generics	Bepotastine besilate	1.5%	Prescription allergy therapy	Comfort, viscosity, and multidose packaging
Optivar and generics	Azelastine HCl	0.05%	Established antihistamine option	Taste reduction and preservative strategy

Epinastine’s disadvantage is limited brand power relative to olopatadine and ketotifen. Its advantage is the ability to enter a mature market with lower active-pharmaceutical-ingredient risk and to target a specific unmet need through delivery technology.

What commercial opportunities exist for epinastine excipient suppliers?

The commercial opportunity is broader than selling epinastine itself. Excipient and packaging suppliers can participate through:

Preservative-free packaging

Demand for preservative-free ophthalmics supports unit-dose blow-fill-seal systems, sterile polymer containers, and multidose valve technologies. A supplier with a validated package and regulatory support can create switching costs for generic manufacturers.

Ophthalmic polymers

Viscosity modifiers, mucoadhesive polymers, and lubricating excipients can support differentiated epinastine products. The strongest opportunity is a formulation that improves comfort without compromising drop size, clarity, sterility, or patient adherence.

Stability platforms

Suppliers can provide low-peroxide excipients, chelators, oxygen-control systems, and light-protective packaging. These inputs may improve shelf life and reduce batch failure risk, which is commercially important in a price-sensitive generic market.

Pediatric and geriatric formats

Oral epinastine products in Asian markets create potential for orally disintegrating tablets, granules, low-dose liquids, and taste-masked formulations. Potential excipient platforms include:

• Mannitol-based orally disintegrating matrices.
• Crospovidone or croscarmellose sodium for rapid disintegration.
• Hydroxypropyl cellulose or polymeric coatings for taste masking.
• Sweeteners and flavor systems compatible with pediatric use.
• Unit-dose sachets for seasonal allergy treatment.

The commercial case depends on jurisdiction. Oral epinastine is not a uniform global product, and a formulation successful in Japan or another Asian market may require a separate regulatory and commercial strategy elsewhere.

What manufacturing and intellectual-property barriers exist?

Epinastine API production is unlikely to be the principal barrier. The more relevant barriers are sterile manufacturing, preservative-free filling, device qualification, and reliable global supply.

Key manufacturing controls include:

• Sterile filtration or validated aseptic processing.
• Low-bioburden water systems.
• Container-closure integrity.
• Extractables and leachables evaluation.
• Delivered-dose uniformity.
• Drop-size control.
• Preservative effectiveness testing where applicable.
• Particulate and subvisible-particle control.
• Photostability and accelerated stability studies.

For a preservative-free product, the container is part of the product’s quality system. A sponsor cannot treat device selection as a secondary packaging decision. The device must protect sterility throughout the in-use period and deliver the labeled dose consistently.

Which companies are positioned to challenge or commercialize epinastine?

Generic pharmaceutical companies with sterile ophthalmic capacity are the most likely competitors. The competitive field includes manufacturers with ANDA portfolios in allergy ophthalmics, contract manufacturers specializing in aseptic liquid products, and packaging suppliers with preservative-free multidose systems.

The principal competitive advantages are:

1. Existing FDA-approved sterile ophthalmic infrastructure.
2. Access to low-cost epinastine hydrochloride API.
3. Established pharmacy and payer distribution.
4. Ability to bundle epinastine with other generic ophthalmic products.
5. Formulation or device patents that support product differentiation.
6. Reliable supply during seasonal allergy demand peaks.

No biosimilar developers are relevant. Licensing opportunities are more likely to involve formulation technology, sterile fill-finish capacity, preservative-free devices, or regional commercialization rights than the epinastine molecule itself.

What generic launch risks exist for epinastine?

Generic entry risk is high for the conventional preserved ophthalmic solution because the product is mature and technically familiar. Price erosion can be substantial once several approved suppliers enter the market.

The principal risks are:

• Low reimbursement and limited pricing power.
• Substitution by olopatadine or ketotifen.
• Retail purchasing decisions based on price.
• Seasonal demand volatility.
• Sterile manufacturing deviations.
• Device supply interruptions.
• Preservative-related tolerability concerns.
• Limited clinical differentiation.

A new formulation can reduce direct price competition, but it must justify a premium through measurable patient benefit, better adherence, lower ocular-surface burden, or easier administration.

Key Takeaways

• Epinastine is a mature, genericized antihistamine with limited core-molecule exclusivity.
• The strongest formulation opportunity is a preservative-free ophthalmic product.
• Multidose preservative-free devices offer better differentiation than routine excipient substitution but require greater technical investment.
• Benzalkonium chloride is the main excipient-related commercial vulnerability in conventional epinastine eye drops.
• Viscosity modifiers, chelators, low-peroxide excipients, and light-protective packaging can support stability and comfort improvements.
• Patent value is likely to come from formulation-device combinations, not broad epinastine composition claims.
• Paragraph IV exposure is relevant only if enforceable formulation or device patents are listed in the Orange Book.
• Biosimilar competition does not apply.
• Oral and nasal opportunities are jurisdiction-specific, with Asia providing the clearest commercial precedent for non-ophthalmic epinastine products.
• The best licensing targets are preservative-free packaging, sterile fill-finish, ophthalmic polymers, and regional commercialization platforms.

FAQs

Can epinastine be reformulated as a preservative-free eye drop?

Yes. A unit-dose presentation is the most direct approach. A preservative-free multidose system is also possible but requires microbial ingress, container-closure, in-use stability, and dose-delivery validation.

Which excipient is most likely to drive epinastine ophthalmic differentiation?

The preservation system is the leading opportunity. Replacing benzalkonium chloride can support a comfort-focused product, particularly for chronic users and patients with ocular-surface sensitivity.

Can a new epinastine excipient combination receive patent protection?

Potentially, but routine substitutions are vulnerable to obviousness challenges. Stronger protection would require defined composition ranges linked to unexpected stability, tolerability, sterility, delivery, or shelf-life performance.

Is epinastine suitable for an orally disintegrating tablet?

Yes. The molecule’s existing oral-market presence in some jurisdictions supports evaluation of orally disintegrating tablets, granules, and pediatric formats. Taste masking and dose flexibility would determine commercial viability.

Does epinastine have biosimilar competition?

No. Epinastine is a synthetic small molecule, so competitors use generic-drug pathways rather than biosimilar applications.

References

1. U.S. Food and Drug Administration. (1999). ELestat (epinastine hydrochloride ophthalmic solution) prescribing information.
2. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
3. Baudouin, C., Labbé, A., Liang, H., Pauly, A., & Brignole-Baudouin, F. (2010). Preservatives in eyedrops: The good, the bad and the ugly. Progress in Retinal and Eye Research, 29(4), 312-334.
4. U.S. Food and Drug Administration. (2023). Approved drug products and therapeutic equivalence evaluations.
5. International Council for Harmonisation. (2003). ICH Q1A(R2): Stability testing of new drug substances and products.